WO2005107705A3 - Extended therapeutic effect ocular implant treatments - Google Patents

Extended therapeutic effect ocular implant treatments Download PDF

Info

Publication number
WO2005107705A3
WO2005107705A3 PCT/US2005/013206 US2005013206W WO2005107705A3 WO 2005107705 A3 WO2005107705 A3 WO 2005107705A3 US 2005013206 W US2005013206 W US 2005013206W WO 2005107705 A3 WO2005107705 A3 WO 2005107705A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic effect
ocular implant
extended therapeutic
ocular
implant treatments
Prior art date
Application number
PCT/US2005/013206
Other languages
French (fr)
Other versions
WO2005107705A2 (en
Inventor
Scott M Whitcup
David A Weber
Original Assignee
Allergan Inc
Scott M Whitcup
David A Weber
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc, Scott M Whitcup, David A Weber filed Critical Allergan Inc
Publication of WO2005107705A2 publication Critical patent/WO2005107705A2/en
Publication of WO2005107705A3 publication Critical patent/WO2005107705A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators

Abstract

Medicaments and methods for treating ocular conditions by inserting an implant comprising an active agent into an ocular site of a patient thereby obtaining an amelioration of a symptom of the ocular condition (i.e. a therapeutic effect) for an extended period of time during which a therapeutic amount or a detectable amount of the active agent is not present at the ocular site.
PCT/US2005/013206 2004-04-30 2005-04-20 Extended therapeutic effect ocular implant treatments WO2005107705A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/837,357 US20050244469A1 (en) 2004-04-30 2004-04-30 Extended therapeutic effect ocular implant treatments
US10/837,357 2004-04-30

Publications (2)

Publication Number Publication Date
WO2005107705A2 WO2005107705A2 (en) 2005-11-17
WO2005107705A3 true WO2005107705A3 (en) 2006-07-27

Family

ID=35187366

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/013206 WO2005107705A2 (en) 2004-04-30 2005-04-20 Extended therapeutic effect ocular implant treatments

Country Status (4)

Country Link
US (14) US20050244469A1 (en)
AR (1) AR048645A1 (en)
TW (1) TWI389693B (en)
WO (1) WO2005107705A2 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8778381B2 (en) 2003-01-09 2014-07-15 Allergan, Inc. Ocular implant made by a double extrusion process
US8905963B2 (en) 2010-08-05 2014-12-09 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US9012437B2 (en) 2000-07-05 2015-04-21 Allergan, Inc. Implants and methods for treating inflammation-mediated conditions of the eye
US9138480B2 (en) 2009-11-09 2015-09-22 Allergan, Inc. Compositions and methods for stimulating hair growth
US9283178B2 (en) 2000-11-29 2016-03-15 Allergan, Inc. Methods for treating edema in the eye and intraocular implants for use therefor
US9417238B2 (en) 2009-01-29 2016-08-16 Forsight Vision4, Inc. Posterior segment drug delivery
US9474756B2 (en) 2014-08-08 2016-10-25 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US9492315B2 (en) 2010-08-05 2016-11-15 Forsight Vision4, Inc. Implantable therapeutic device
US9526654B2 (en) 2013-03-28 2016-12-27 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances

Families Citing this family (192)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US20060280774A1 (en) * 1995-06-02 2006-12-14 Allergan, Inc. Compositions and methods for treating glaucoma
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
MXPA06006406A (en) 2003-12-05 2007-03-21 Adnexus Therapeutics Inc Inhibitors of type 2 vascular endothelial growth factor receptors.
US20080220049A1 (en) * 2003-12-05 2008-09-11 Adnexus, A Bristol-Myers Squibb R&D Company Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
US20050232972A1 (en) 2004-04-15 2005-10-20 Steven Odrich Drug delivery via punctal plug
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US8722097B2 (en) * 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
CA2572592C (en) 2004-07-02 2015-09-08 Eliot Lazar Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such a delivery device
ES2432556T3 (en) 2004-08-04 2013-12-04 Evonik Corporation Methods for manufacturing supply devices and their devices
US9993558B2 (en) 2004-10-01 2018-06-12 Ramscor, Inc. Sustained release eye drop formulations
US8541413B2 (en) * 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
JP5682991B2 (en) * 2004-10-01 2015-03-11 ラムズコア， インコーポレイテッド Convenient implantable sustained release drug formulation
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
WO2006076922A1 (en) * 2005-01-20 2006-07-27 I-Shine Danmark Aps Apparatus for dispension of liquid
US7931909B2 (en) * 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
EP2462959B1 (en) * 2005-07-12 2016-06-22 Ampio Pharmaceuticals, Inc. Methods and products for treatment of diseases
US8083787B2 (en) 2005-07-18 2011-12-27 Tearscience, Inc. Method and apparatus for treating meibomian gland dysfunction
US7981145B2 (en) * 2005-07-18 2011-07-19 Tearscience Inc. Treatment of meibomian glands
US20080114423A1 (en) 2006-05-15 2008-05-15 Grenon Stephen M Apparatus for inner eyelid treatment of meibomian gland dysfunction
US20070060988A1 (en) 2005-07-18 2007-03-15 Grenon Stephen M Melting meibomian gland obstructions
WO2013003594A2 (en) 2011-06-28 2013-01-03 Tearscience, Inc. Methods and systems for treating meibomian gland dysfunction using radio-frequency energy
US7981095B2 (en) 2005-07-18 2011-07-19 Tearscience, Inc. Methods for treating meibomian gland dysfunction employing fluid jet
US20090043365A1 (en) 2005-07-18 2009-02-12 Kolis Scientific, Inc. Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma
US7981146B2 (en) 2006-05-15 2011-07-19 Tearscience Inc. Inner eyelid treatment for treating meibomian gland dysfunction
US8950405B2 (en) 2006-05-15 2015-02-10 Tearscience, Inc. Treatment of obstructive disorders of the eye or eyelid
WO2007037849A2 (en) 2005-09-16 2007-04-05 Allergan, Inc. Compositions and methods for the intraocular transport of therapeutic agents
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
US20070093461A1 (en) * 2005-10-26 2007-04-26 Bausch & Lomb Incorporated Effect of Loteprednol etabonate on vascular dysfunction
US20070203144A1 (en) * 2006-01-17 2007-08-30 Allergan, Inc. Use of Memantine and Brimonidine to Attenuate Vitreoretinal Vascular Endothelial Growth Factor (VEGF) Protein Levels in Animals
US20070178138A1 (en) * 2006-02-01 2007-08-02 Allergan, Inc. Biodegradable non-opthalmic implants and related methods
US20070248646A1 (en) * 2006-02-16 2007-10-25 Ali Hafezi-Moghadam Use of azurocidin inhibitors in prevention and treatment of ocular vascular leakage
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
EP3449873A1 (en) 2006-03-31 2019-03-06 Mati Therapeutics Inc. Drug delivery structures and compositions for nasolacrimal system
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
US7981147B2 (en) 2006-05-15 2011-07-19 Tearscience, Inc. Outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8128673B2 (en) * 2006-05-15 2012-03-06 Tearscience, Inc. System for inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8137390B2 (en) 2006-05-15 2012-03-20 Tearscience, Inc. System for providing heat treatment and heat loss reduction for treating meibomian gland dysfunction
US8128674B2 (en) 2006-05-15 2012-03-06 Tearscience, Inc. System for outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8007524B2 (en) 2006-05-15 2011-08-30 Tearscience, Inc. Heat treatment and heat loss reduction for treating meibomian gland dysfunction
US7976573B2 (en) 2006-05-15 2011-07-12 Tearscience, Inc. Inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
US9314369B2 (en) 2006-05-15 2016-04-19 Tearscience, Inc. System for inner eyelid treatment of meibomian gland dysfunction
DK2319517T3 (en) * 2006-06-01 2013-12-09 Novagali Pharma Sa APPLICATION OF PRODRUGS TO OCULAR, INTRAVENOUS ADMINISTRATION
US8802128B2 (en) 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
WO2008027069A1 (en) * 2006-08-21 2008-03-06 Tearscience, Inc. Method and apparatus for treating meibomian gland dysfunction employing fluid
BRPI0604577B8 (en) * 2006-08-31 2021-05-25 Univ Minas Gerais pharmaceutical formulation for intraocular drug administration and procurement process
EP3156415A1 (en) 2006-11-22 2017-04-19 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US20080175831A1 (en) * 2006-12-21 2008-07-24 Macknik Stephen L Neuroprotection by blood flow stabilization
EP2101697A4 (en) * 2007-01-09 2010-10-20 Tearscience Inc Treatment of meibomian glands
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US8231892B2 (en) * 2007-05-24 2012-07-31 Allergan, Inc. Biodegradable drug delivery system
ES2732555T3 (en) 2007-09-07 2019-11-25 Mati Therapeutics Inc Tear implants and related methods
EP2205193A2 (en) 2007-09-07 2010-07-14 QLT Plug Delivery, Inc. Lacrimal implant detection
MX2010002616A (en) 2007-09-07 2010-08-04 Qlt Plug Delivery Inc Drug cores for sustained release of therapeutic agents.
EP2222281B1 (en) 2007-12-20 2018-12-05 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
USD613408S1 (en) 2008-02-06 2010-04-06 Tearscience, Inc. Eye treatment head gear
USD617443S1 (en) 2008-02-06 2010-06-08 Tearscience, Inc. Eye treatment goggles
AU2009213141A1 (en) 2008-02-14 2009-08-20 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind EGFR
CN102014816B (en) * 2008-02-18 2015-04-15 马缇医疗股份有限公司 Lacrimal implants and related methods
BRPI0909630B8 (en) 2008-03-11 2021-05-25 Alcon Inc aqueous suspension composition particularly suitable for injection into the eye
JP5552482B2 (en) 2008-04-30 2014-07-16 キュー エル ティー インク． Composite lacrimal insert and related methods
BRPI0912182A2 (en) 2008-05-09 2015-10-06 Qlt Plug Delivery Inc prolonged release distribution of active agents to treat glaucoma and ocular hypertension
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10588855B2 (en) * 2008-05-12 2020-03-17 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10064819B2 (en) * 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
EP2276439A4 (en) 2008-05-12 2013-11-27 Univ Utah Res Found Intraocular drug delivery device and associated methods
EP2291399B1 (en) 2008-05-22 2014-06-25 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
US8877225B2 (en) * 2008-06-03 2014-11-04 Tolmar Therapeutics, Inc. Controlled release copolymer formulation with improved release kinetics
US8821870B2 (en) 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
US20100104654A1 (en) 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
TWI496582B (en) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 Bispecific egfr/igfir binding molecules
WO2010083129A2 (en) * 2009-01-13 2010-07-22 The Regents Of The University Of California Implantable delivery vehicle for ocular delivery of muscarinic antagonists
WO2010085609A2 (en) * 2009-01-23 2010-07-29 Surmodics Pharmaceuticals, Inc. Controlled release systems from polymer blends
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
WO2010093873A2 (en) 2009-02-12 2010-08-19 Incept, Llc Drug delivery through hydrogel plugs
WO2010096822A2 (en) * 2009-02-23 2010-08-26 Qlt Plug Delivery, Inc. Lacrimal implants and related methods
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
US20100278897A1 (en) * 2009-05-01 2010-11-04 Allergan, Inc. Intraocular bioactive agent delivery system with molecular partitioning system
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
PL2326332T3 (en) * 2009-06-22 2013-05-31 Ampio Pharmaceuticals Inc Method for treatment of diseases
MX2011013984A (en) * 2009-06-22 2012-06-01 Dmi Acquisition Corp Methods and products for treatment of diseases.
USD638128S1 (en) 2009-10-06 2011-05-17 Tearscience, Inc. Ocular device design
EP2394636B1 (en) * 2010-05-28 2014-03-19 Novagali Pharma S.A. Method for treating retinal conditions using an intraocular tamponade
ES2758554T3 (en) 2009-12-08 2020-05-05 Univ Case Western Reserve Range amino acids for treatment of eye disorders
US8529492B2 (en) 2009-12-23 2013-09-10 Trascend Medical, Inc. Drug delivery devices and methods
CA2785468A1 (en) * 2009-12-23 2011-06-30 Psivida Us, Inc. Sustained release delivery devices
BR112012018134B1 (en) 2010-01-22 2022-11-29 Allergan, Inc USE OF A THERAPEUTIC AGENT AND BIODEGRADABLE SUSTAINED RELEASE IMPLANT TO TREAT AN OCULAR CONDITION
US8889193B2 (en) 2010-02-25 2014-11-18 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
WO2011146483A1 (en) * 2010-05-17 2011-11-24 Aerie Pharmaceuticals, Inc. Drug delivery devices for delivery of ocular therapeutic agents
WO2011150133A2 (en) 2010-05-26 2011-12-01 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
EP2595602B1 (en) 2010-07-21 2018-05-23 Allergan, Inc. SUSTAINED RELEASE siRNA FOR OCULAR DRUG DELIVERY
US10617557B2 (en) 2010-08-05 2020-04-14 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
WO2012039979A2 (en) 2010-09-10 2012-03-29 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
CN104758118B (en) 2010-10-15 2018-04-06 科尼尔赛德生物医学公司 For entering the device of eyes
US20140031769A1 (en) 2010-11-19 2014-01-30 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US9327037B2 (en) 2011-02-08 2016-05-03 The Johns Hopkins University Mucus penetrating gene carriers
EP3967297A1 (en) 2011-04-29 2022-03-16 Allergan, Inc. Sustained release latanoprost implant
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
EP2726016B1 (en) 2011-06-28 2023-07-19 ForSight Vision4, Inc. An apparatus for collecting a sample of fluid from a reservoir chamber of a therapeutic device for the eye
EP2739252A4 (en) 2011-08-05 2015-08-12 Forsight Vision4 Inc Small molecule delivery with implantable therapeutic device
EP2750660B1 (en) 2011-08-29 2016-10-12 Mati Therapeutics Inc. Sustained release delivery of active agents to treat glaucoma and ocular hypertension
US9974685B2 (en) 2011-08-29 2018-05-22 Mati Therapeutics Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
RS61758B1 (en) 2011-09-16 2021-05-31 Forsight Vision4 Inc Fluid exchange apparatus
US10226417B2 (en) 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
US9415020B2 (en) 2012-01-19 2016-08-16 The Johns Hopkins University Nanoparticle formulations with enhanced mucosal penetration
US10010448B2 (en) 2012-02-03 2018-07-03 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
CA2867381C (en) 2012-03-16 2016-09-20 The Johns Hopkins University Controlled release formulations for the delivery of hif-1 inhibitors
AU2013232300B2 (en) 2012-03-16 2015-12-17 The Johns Hopkins University Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
EP4008355A1 (en) 2012-05-03 2022-06-08 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
EP3808339A1 (en) 2012-05-03 2021-04-21 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
JP6392209B2 (en) 2012-05-04 2018-09-19 ザ・ジョンズ・ホプキンス・ユニバーシティー Lipid-based drug carriers for rapid permeation through the mucus lining
WO2014031857A2 (en) 2012-08-22 2014-02-27 Tearscience, Inc. Apparatuses and methods for diagnosing and/or treating lipid transport deficiency in ocular tear films, and related components and devices
EP2900250B1 (en) * 2012-09-27 2018-11-07 Allergan, Inc. Biodegradable drug delivery systems for the sustained release of proteins
WO2014066653A1 (en) * 2012-10-26 2014-05-01 Allergan, Inc. Ketorolac-containing sustained release intraocular drug delivery systems
WO2014066658A1 (en) * 2012-10-26 2014-05-01 Allergan, Inc. Ketorolac-containing sustained release drug delivery systems
WO2014066644A1 (en) * 2012-10-26 2014-05-01 Allergan, Inc. Ketorolac-containing sustained release drug delivery systems
CA2890471C (en) * 2012-11-08 2021-07-27 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
MX366404B (en) 2012-11-15 2019-07-08 Apellis Pharmaceuticals Inc Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods.
US9351979B2 (en) 2012-12-19 2016-05-31 Ampio Pharmaceuticals, Inc. Methods of treatment of diseases
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
US20140234389A1 (en) 2013-02-15 2014-08-21 Allergan, Inc. Sustained drug delivery implant
EP2968113B8 (en) 2013-03-14 2020-10-28 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
US10308687B2 (en) 2013-03-15 2019-06-04 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
US9763827B2 (en) 2013-04-30 2017-09-19 Tear Film Innovations, Inc. Systems and methods for the treatment of eye conditions
EP3744391B1 (en) 2013-04-30 2023-03-01 Alcon Inc. Systems for the treatment of eye conditions
WO2014179698A2 (en) 2013-05-03 2014-11-06 Clearside Biomedical, Inc. Apparatus and methods for ocular injection
WO2014197317A1 (en) 2013-06-03 2014-12-11 Clearside Biomedical, Inc. Apparatus and methods for drug delivery using multiple reservoirs
TR201802759T4 (en) 2013-10-31 2018-03-21 Allergan Inc Prostamide-containing intraocular implants and methods of use.
CA2929689A1 (en) * 2013-11-15 2015-05-21 Allergan, Inc. Methods of treatment of ocular conditions with a sustained drug delivery implant
AU2014360184B2 (en) * 2013-12-06 2020-07-23 Allergan, Inc Intracameral implant for treatment of an ocular condition
WO2015127389A1 (en) 2014-02-23 2015-08-27 The Johns Hopkins University Hypotonic enema formulations and methods of use
US11338059B2 (en) 2014-05-12 2022-05-24 Gholam A. Peyman Method of corneal and scleral inlay crosslinking and preservation
US10881503B2 (en) 2014-05-12 2021-01-05 Gholam A. Peyman Method of corneal transplantation or corneal inlay implantation with cross-linking
US11045352B2 (en) 2014-05-12 2021-06-29 Gholam A. Peyman Methods for treatment of dry eye and other acute or chronic inflammatory processes
US11565023B2 (en) 2014-05-12 2023-01-31 Gholam A. Peyman Method of corneal transplantation or corneal inlay implantation with cross-linking
US10925889B2 (en) 2014-05-12 2021-02-23 Gholam A. Peyman Method of treating, reducing, or alleviating a medical condition in a patient
US11666777B2 (en) 2014-05-12 2023-06-06 Gholam A. Peyman Photodynamic therapy technique for preventing damage to the fovea of the eye or another body portion of a patient
US11648261B2 (en) 2014-05-12 2023-05-16 Gholam A. Peyman Method of treating, reducing, or alleviating a medical condition in a patient
US10583221B2 (en) 2014-05-12 2020-03-10 Gholam A. Peyman Method of corneal transplantation or corneal inlay implantation with cross-linking
US20150342875A1 (en) 2014-05-29 2015-12-03 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
CN106794321A (en) 2014-06-20 2017-05-31 科尼尔赛德生物医学公司 Variable-diameter intubation and for controlling the method to the insertion depth of drug delivery
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
RU2695563C2 (en) 2014-07-15 2019-07-24 Форсайт Вижн4, Инк. Method and device for eye implant delivery
CA3200870A1 (en) 2014-07-30 2016-02-04 Massachusetts Eye And Ear Infirmary Methotrexate for proliferative vitreoretinopathy
JP7037360B2 (en) 2014-11-10 2022-03-16 フォーサイト・ビジョン フォー・インコーポレーテッド Expandable drug delivery device
EP3250184A1 (en) 2015-01-27 2017-12-06 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
WO2016196365A1 (en) * 2015-05-29 2016-12-08 Envisia Therapeutics, Inc. Implant for treatment of an ocular condition
AR106018A1 (en) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
EP3340982B1 (en) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
EP4349363A2 (en) 2015-10-07 2024-04-10 Apellis Pharmaceuticals, Inc. Dosing regimens
WO2017087902A1 (en) 2015-11-20 2017-05-26 Forsight Vision4, Inc. Porous structures for extended release drug delivery devices
US10765665B2 (en) 2015-11-24 2020-09-08 Melin Jeffrey Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases
US11066465B2 (en) 2015-12-30 2021-07-20 Kodiak Sciences Inc. Antibodies and conjugates thereof
US20170224815A1 (en) * 2016-02-09 2017-08-10 Nima Tirgan Method of Preventing and Treating Retinal Microvasculature Inflammation Using C-Met Signaling Pathway Inhibition
EP3413851B1 (en) 2016-02-10 2023-09-27 Clearside Biomedical, Inc. Packaging
MX2018012021A (en) 2016-04-05 2019-01-24 Forsight Vision4 Inc Implantable ocular drug delivery devices.
US11318043B2 (en) 2016-04-20 2022-05-03 Dose Medical Corporation Bioresorbable ocular drug delivery device
JP2019514581A (en) 2016-05-02 2019-06-06 クリアサイド バイオメディカル，インコーポレイテッド Systems and methods for ocular drug delivery
CN109641874A (en) 2016-05-10 2019-04-16 C4医药公司 C for target protein degradation3The glutarimide degron body of carbon connection
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
KR20190036520A (en) 2016-06-27 2019-04-04 아칠리온 파르마세우티칼스 인코포레이티드 Quinazoline and indole compounds for the treatment of medical disorders
US10974063B2 (en) 2016-06-30 2021-04-13 Alcon Inc. Light therapy for eyelash growth
MX2019000200A (en) 2016-07-01 2019-09-26 G1 Therapeutics Inc Pyrimidine-based antiproliferative agents.
IL264764B2 (en) 2016-08-12 2024-02-01 Clearside Biomedical Inc Devices and methods for adjusting the insertion depth of a needle for medicament delivery
JP2020514404A (en) * 2016-12-27 2020-05-21 ユニバーシティー オブ ユタ リサーチ ファウンデーションＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｕｔａｈ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ Intraocular drug delivery device and related methods
AU2018249627A1 (en) 2017-04-07 2019-10-31 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
US11638833B2 (en) 2017-08-02 2023-05-02 Multi Radiance Medical Reducing light polution in photobiomodulation therapy of a patients eye
BR112020002313B1 (en) 2017-08-02 2022-04-19 Multi Radiance Medical System and method for directing light into a patient's eye
BR112020010053A2 (en) 2017-11-21 2020-11-03 Forsight Vision4, Inc. fluid change device for expandable door release system and methods of using it
EP3773576A4 (en) 2018-03-26 2021-12-29 C4 Therapeutics, Inc. Cereblon binders for the degradation of ikaros
WO2019221959A1 (en) * 2018-05-16 2019-11-21 Peyman Gholam A Method of treating, reducing, or alleviating a medical condition in a patient
CN113365617A (en) 2018-10-16 2021-09-07 乔治亚州立大学研究基金会股份有限公司 Carbon monoxide prodrugs for the treatment of medical conditions
US20220105042A1 (en) * 2019-02-01 2022-04-07 The University Of North Carolina At Chapel Hill Polymeric implants with high drug loading and long-acting drug release and methods of making the same
US11707518B2 (en) 2019-04-28 2023-07-25 Gholam A. Peyman Method of treating, reducing, or alleviating a medical condition in a patient
GB2601922A (en) 2019-06-27 2022-06-15 Layerbio Inc Ocular device delivery methods and systems
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2023133455A1 (en) * 2022-01-06 2023-07-13 Clearside Biomedical, Inc. Compositions and methods for treating macular edema associated with uveitis
US11911385B1 (en) 2022-12-14 2024-02-27 Aldeyra Therapeutics, Inc. Methotrexate treatment methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991018940A1 (en) * 1990-06-04 1991-12-12 Nova Pharmaceutical Corporation Branched polyanhydrides
WO2002002076A2 (en) * 2000-07-05 2002-01-10 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
WO2004062649A2 (en) * 2003-01-09 2004-07-29 Allergan, Inc. Biodegradable ocular implant

Family Cites Families (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE430539C (en) 1922-04-21 1926-06-23 J G Farbenindustrie Akt Ges Process for the preparation of ethylene chloride
DE488401C (en) 1929-05-18 1929-12-27 Sydney Ferdinand Blanch Car body with wooden framework and plywood walls, especially for motor vehicles
DE654256C (en) 1936-09-26 1937-12-18 Dornier Werke Gmbh Device for protecting a screw spindle, especially for retractable aircraft chassis
NL297357A (en) * 1962-08-31
US3416530A (en) 1966-03-02 1968-12-17 Richard A. Ness Eyeball medication dispensing tablet
US3986510A (en) * 1971-09-09 1976-10-19 Alza Corporation Bioerodible ocular device
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3914402A (en) * 1973-06-14 1975-10-21 Alza Corp Ophthalmic dosage form, for releasing medication over time
SE390255B (en) * 1974-02-18 1976-12-13 N G Y Torphammar RELEASE DEVICE PREFERRED FOR A SAFETY BELT IN A VEHICLE
US3961628A (en) * 1974-04-10 1976-06-08 Alza Corporation Ocular drug dispensing system
US3921632A (en) 1974-08-16 1975-11-25 Frank M Bardani Implant device
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4180646A (en) 1975-01-28 1979-12-25 Alza Corporation Novel orthoester polymers and orthocarbonate polymers
US4144317A (en) * 1975-05-30 1979-03-13 Alza Corporation Device consisting of copolymer having acetoxy groups for delivering drugs
US4014334A (en) * 1976-02-02 1977-03-29 Alza Corporation Laminated osmotic system for dispensing beneficial agent
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4201210A (en) * 1976-06-22 1980-05-06 The United States Of America As Represented By The Secretary Of Agriculture Veterinary ocular ring device for sustained drug release
US4186184A (en) * 1977-12-27 1980-01-29 Alza Corporation Selective administration of drug with ocular therapeutic system
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4300557A (en) 1980-01-07 1981-11-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for treating intraocular malignancies
US4402979A (en) * 1980-03-21 1983-09-06 Merck & Co., Inc. & Laboratories Ophthalmic formulations of 5-fluoro-2-methyl-1-(p-methylthiobenzylidene)-3-indenylacetic acid
US4304765A (en) 1980-10-14 1981-12-08 Alza Corporation Ocular insert housing steroid in two different therapeutic forms
DE3168032D1 (en) 1980-11-10 1985-02-14 Alza Corp Erodible polymer containing erosion rate modifier
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
JPS58126435U (en) * 1982-02-19 1983-08-27 オリンパス光学工業株式会社 Aperture control circuit for TTL auto strobe
US4451254A (en) * 1982-03-15 1984-05-29 Eli Lilly And Company Implant system
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
DE3220156C2 (en) * 1982-05-28 1990-01-25 Heida Houston Tex. Thurlow Cooking and roasting utensils with lids provided with metal handles, in particular stainless steel handles
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
IT1229075B (en) 1985-04-05 1991-07-17 Fidia Farmaceutici Topical compsn. contg. hyaluronic acid deriv. as vehicle
US4478818A (en) * 1982-12-27 1984-10-23 Alza Corporation Ocular preparation housing steroid in two different therapeutic forms
US4521210A (en) * 1982-12-27 1985-06-04 Wong Vernon G Eye implant for relieving glaucoma, and device and method for use therewith
US6309669B1 (en) * 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US6217911B1 (en) * 1995-05-22 2001-04-17 The United States Of America As Represented By The Secretary Of The Army sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres
US5082655A (en) * 1984-07-23 1992-01-21 Zetachron, Inc. Pharmaceutical composition for drugs subject to supercooling
US4629621A (en) * 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
US4668506A (en) * 1985-08-16 1987-05-26 Bausch & Lomb Incorporated Sustained-release formulation containing and amino acid polymer
US4966849A (en) * 1985-09-20 1990-10-30 President And Fellows Of Harvard College CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression
DE3612212A1 (en) * 1986-04-11 1987-10-15 Basf Ag METHOD FOR PRODUCING SOLID PHARMACEUTICAL FORMS
US4756911A (en) * 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
US4959217A (en) * 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US5322691A (en) * 1986-10-02 1994-06-21 Sohrab Darougar Ocular insert with anchoring protrusions
US4863457A (en) * 1986-11-24 1989-09-05 Lee David A Drug delivery device
US5006342A (en) * 1986-12-22 1991-04-09 Cygnus Corporation Resilient transdermal drug delivery device
DE3734223A1 (en) 1987-10-09 1989-04-20 Boehringer Ingelheim Kg IMPLANTABLE, BIODEGRADABLE ACTIVE SUBSTANCE RELEASE SYSTEM
US4997652A (en) * 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US4853224A (en) 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4945089A (en) * 1987-12-29 1990-07-31 Alcon Laboratories, Inc. Use of tetrahydrocortexolone to prevent elevations in intraocular pressure caused by corticosteroids
US4865846A (en) * 1988-06-03 1989-09-12 Kaufman Herbert E Drug delivery system
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
DE68929563D1 (en) 1988-09-06 2009-03-05 Pfizer Health Ab Prostaglandin derivatives for the treatment of glaucoma and ocular hypertension
US5004601A (en) * 1988-10-14 1991-04-02 Zetachron, Inc. Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith
US5019400A (en) * 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5028624A (en) * 1989-07-27 1991-07-02 Allergan, Inc. Intraocular pressure reducing 9,15-diacyl prostaglandins
CA2021316C (en) 1989-07-27 2000-10-24 Ming Fai Chan Intraocular pressure reducing 11-acyl prostaglandins
US5034413A (en) * 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
SG49267A1 (en) * 1989-08-14 1998-05-18 Photogenesis Inc Surgical instrument and cell isolation and transplantation
US5112614A (en) * 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
US5268178A (en) 1989-09-25 1993-12-07 The Board Of Regents, The University Of Texas System Biodegradable antibiotic implants and methods of their use in treating and preventing infections
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5660851A (en) * 1989-12-26 1997-08-26 Yissum Research Development Company Of The Hebrew Univ. Of Jerusalem Ocular inserts
ES2064101T3 (en) 1990-04-02 1995-01-16 Pfizer THYROSINE KINASE INHIBITORS BENZYLPHOSPHONIC ACID COMPOUNDS.
US5075115A (en) 1990-04-02 1991-12-24 Fmc Corporation Process for polymerizing poly(lactic acid)
DK0474098T3 (en) 1990-08-30 1994-05-02 Senju Pharma Co Controlled drug release agent
KR0185215B1 (en) * 1990-11-30 1999-05-01 요시다 쇼오지 A controlled-release pharmaceutical preparation for intra-ocular implant
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
JPH06503095A (en) 1991-05-29 1994-04-07 ファイザー・インコーポレーテッド Tricyclic polyhydroxy tyrosine kinase inhibitor
DE69213739T2 (en) * 1991-06-21 1997-02-20 Genetics Inst MEDICINAL PRODUCTS CONTAINING OSTEOGENIC PROTEINS
US5356629A (en) * 1991-07-12 1994-10-18 United States Surgical Corporation Composition for effecting bone repair
US5169638A (en) 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
CA2425841C (en) 1991-11-22 2006-01-10 Alcon Laboratories, Inc. Angiostatic steroids
US5543154A (en) * 1991-12-27 1996-08-06 Merck & Co., Inc. Controlled release nifedipine delivery device
US6045791A (en) * 1992-03-06 2000-04-04 Photogenesis, Inc. Retinal pigment epithelium transplantation
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
US5384333A (en) * 1992-03-17 1995-01-24 University Of Miami Biodegradable injectable drug delivery polymer
US5178635A (en) 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
AU672224B2 (en) 1992-08-06 1996-09-26 Warner-Lambert Company 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and whichhave antitumor properties
US5972991A (en) * 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5330992A (en) * 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
HU225646B1 (en) 1992-10-28 2007-05-29 Genentech Inc Hvegf receptors as vascular endothelial cell growth factor antagonists
US5574066A (en) 1992-10-28 1996-11-12 Allergan Intraocular pressure reducing 15-acyl prostaglandins
US5314419A (en) * 1992-10-30 1994-05-24 Pelling George E Method for dispensing ophthalmic drugs to the eye
ATE183083T1 (en) * 1992-11-18 1999-08-15 Fujisawa Pharmaceutical Co PHARMACEUTICAL PREPARATION WITH PROLONGED ACTION
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US5538735A (en) 1993-02-19 1996-07-23 Ahn; Sam S. Method of making a drug delivery system using hollow fibers
US5707643A (en) * 1993-02-26 1998-01-13 Santen Pharmaceutical Co., Ltd. Biodegradable scleral plug
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US5385887A (en) * 1993-09-10 1995-01-31 Genetics Institute, Inc. Formulations for delivery of osteogenic proteins
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US6051576A (en) * 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
DE4403326C1 (en) * 1994-02-03 1995-06-22 Hans Reinhard Prof Dr Koch Intraocular lens arrangement for astigmatism correction
US5516522A (en) 1994-03-14 1996-05-14 Board Of Supervisors Of Louisiana State University Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same
US5773021A (en) * 1994-03-14 1998-06-30 Vetoquinol S.A. Bioadhesive ophthalmic insert
US5755785A (en) * 1994-08-12 1998-05-26 The University Of South Florida Sutureless corneal transplantation method
US6063116A (en) * 1994-10-26 2000-05-16 Medarex, Inc. Modulation of cell proliferation and wound healing
US6369116B1 (en) 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5693335A (en) 1995-06-07 1997-12-02 Cygnus, Inc. Skin permeation enhancer composition for use with sex steroids
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
BR9607752B1 (en) 1996-01-24 2009-05-05 controlled release microcapsule pharmaceutical formulation.
US6046187A (en) * 1996-09-16 2000-04-04 Children's Medical Center Corporation Formulations and methods for providing prolonged local anesthesia
JP2002514194A (en) 1996-11-19 2002-05-14 ザ スキーペンズ アイ リサーチ インスティテュート インコーポレイテッド Topical use of IL-1RA in rejection of corneal transplantation or eye disease
US5941250A (en) * 1996-11-21 1999-08-24 University Of Louisville Research Foundation Inc. Retinal tissue implantation method
DE69816980T2 (en) * 1997-03-31 2004-07-22 Alza Corp., Palo Alto IMPLANTABLE DIFFUSION DELIVERY SYSTEM
WO1999001156A1 (en) 1997-07-02 1999-01-14 Santen Pharmaceutical Co., Ltd. Polylactic acid scleral plugs
JP2001513369A (en) * 1997-08-11 2001-09-04 アラーガン・セイルズ・インコーポレイテッド Sterile bioerodible implant devices and methods with improved biocompatibility
US6306426B1 (en) * 1997-08-11 2001-10-23 Allergan Sales, Inc. Implant device with a retinoid for improved biocompatibility
US5902598A (en) 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
US6329369B1 (en) 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
US6841684B2 (en) * 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
US6196993B1 (en) 1998-04-20 2001-03-06 Eyelab Group, Llc Ophthalmic insert and method for sustained release of medication to the eye
WO2000002564A1 (en) 1998-07-10 2000-01-20 The University Of Sydney Prophylactic treatments of neovascularisation in macular degeneration
CA2351734A1 (en) 1998-11-20 2000-06-02 University Of Connecticut Generic integrated implantable potentiostat telemetry unit for electrochemical sensors
US6217895B1 (en) * 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US7335803B2 (en) * 2001-10-19 2008-02-26 Allergan, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
US6545182B2 (en) * 2000-04-13 2003-04-08 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
US20040170665A1 (en) * 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
NZ521185A (en) 2000-07-14 2005-02-25 Allergan Inc Compositions containing alpha-2-adrenergic agonist components
WO2002058730A2 (en) 2000-11-01 2002-08-01 Allergan, Inc. Compositions for treatment of ocular neovascularization
AU3649502A (en) * 2000-11-29 2002-06-11 Oculex Pharm Inc Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US6534542B2 (en) * 2001-02-27 2003-03-18 Allergen Sales, Inc. (2-hydroxy)ethyl-thioureas useful as modulators of α2B adrenergic receptors
US6713081B2 (en) * 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
EA006746B1 (en) * 2001-11-09 2006-04-28 Айтек Фармасьютикалз Methods for treating ocular neovascular diseases
US6541504B1 (en) * 2002-04-03 2003-04-01 Allergan Sales, Llc (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
JP2005532313A (en) 2002-05-07 2005-10-27 コントロール・デリバリー・システムズ・インコーポレイテッド Method for forming drug delivery device
US7276522B2 (en) 2002-05-21 2007-10-02 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US20040266776A1 (en) 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US7091232B2 (en) * 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7345065B2 (en) * 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
PL223153B1 (en) 2002-09-18 2016-10-31 Allergan Inc Methods and apparatus for delivery of ocular implants
NZ539810A (en) * 2002-11-06 2008-03-28 Alza Corp Controlled release injectable depot formulations
US20050048099A1 (en) * 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US7141597B2 (en) 2003-09-12 2006-11-28 Allergan, Inc. Nonsedating α-2 agonists
US20050059664A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Novel methods for identifying improved, non-sedating alpha-2 agonists
DE10335138A1 (en) 2003-07-31 2005-02-17 Giesecke & Devrient Gmbh Procedures for the specification of printing and control of the print quality of securities
US20050161695A1 (en) 2003-09-05 2005-07-28 Sae Magnetics (H.K.) Ltd. Systems and methods having a metal-semiconductor-metal (MSM) photodetector with buried oxide layer
US20050059744A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20050058696A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
AU2005209201B2 (en) * 2004-01-20 2010-06-03 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US7691381B2 (en) * 2004-04-15 2010-04-06 Allergan, Inc. Stabilized biodegradable neurotoxin implants
US20060182783A1 (en) 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US20050244472A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20070059336A1 (en) 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US7993634B2 (en) * 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
JP2008505978A (en) * 2004-07-12 2008-02-28 アラーガン、インコーポレイテッド Ophthalmic composition and eye disease treatment method
US20060204548A1 (en) 2005-03-01 2006-09-14 Allergan, Inc. Microimplants for ocular administration
US20060233857A1 (en) 2005-04-14 2006-10-19 Amsden Brian G Degradable elastomeric network
US20070178138A1 (en) 2006-02-01 2007-08-02 Allergan, Inc. Biodegradable non-opthalmic implants and related methods
US20070260203A1 (en) 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
US20070298073A1 (en) 2006-06-23 2007-12-27 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991018940A1 (en) * 1990-06-04 1991-12-12 Nova Pharmaceutical Corporation Branched polyanhydrides
WO2002002076A2 (en) * 2000-07-05 2002-01-10 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
WO2004062649A2 (en) * 2003-01-09 2004-07-29 Allergan, Inc. Biodegradable ocular implant

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012437B2 (en) 2000-07-05 2015-04-21 Allergan, Inc. Implants and methods for treating inflammation-mediated conditions of the eye
US9283178B2 (en) 2000-11-29 2016-03-15 Allergan, Inc. Methods for treating edema in the eye and intraocular implants for use therefor
US9592242B2 (en) 2000-11-29 2017-03-14 Allergan, Inc. Methods for treating edema in the eye and intraocular implants for use therefor
US8778381B2 (en) 2003-01-09 2014-07-15 Allergan, Inc. Ocular implant made by a double extrusion process
US9417238B2 (en) 2009-01-29 2016-08-16 Forsight Vision4, Inc. Posterior segment drug delivery
US9138480B2 (en) 2009-11-09 2015-09-22 Allergan, Inc. Compositions and methods for stimulating hair growth
US8905963B2 (en) 2010-08-05 2014-12-09 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US9033911B2 (en) 2010-08-05 2015-05-19 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US9492315B2 (en) 2010-08-05 2016-11-15 Forsight Vision4, Inc. Implantable therapeutic device
US9526654B2 (en) 2013-03-28 2016-12-27 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
US9474756B2 (en) 2014-08-08 2016-10-25 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof

Also Published As

Publication number Publication date
US20080241221A1 (en) 2008-10-02
US20080233171A1 (en) 2008-09-25
US20050244469A1 (en) 2005-11-03
US9233071B2 (en) 2016-01-12
US20080233172A1 (en) 2008-09-25
US20150133559A1 (en) 2015-05-14
US20080241222A1 (en) 2008-10-02
WO2005107705A2 (en) 2005-11-17
AR048645A1 (en) 2006-05-10
US20080241220A1 (en) 2008-10-02
US8911768B2 (en) 2014-12-16
US20080172014A1 (en) 2008-07-17
US20130302324A1 (en) 2013-11-14
TWI389693B (en) 2013-03-21
US8802129B2 (en) 2014-08-12
US20060233859A1 (en) 2006-10-19
TW200538135A (en) 2005-12-01
US20080241219A1 (en) 2008-10-02
US20140328835A1 (en) 2014-11-06
US20080233173A1 (en) 2008-09-25
US20120329850A1 (en) 2012-12-27

Similar Documents

Publication Publication Date Title
WO2005107705A3 (en) Extended therapeutic effect ocular implant treatments
AU2018213993B2 (en) Methods and devices for catheter advancement and delivery of substances therethrough
WO2006014484A3 (en) Methods and devices for the treatment of ocular conditions
WO2007035473A3 (en) Pharmaceutical delivery device and method for providing ocular treatment
WO2007115261A3 (en) Drug delivery methods, structures, and compositions for nasolacrimal system
WO2007127362A3 (en) Apparatus and method for treating cardiovascular diseases
WO2008027371A3 (en) Low profile bioactive agent delivery device
WO2008070262A3 (en) Apparatus and method for targeting a body tissue
WO2008073670A3 (en) Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor
MXPA05008461A (en) Kit for applying drug coating to a medical device in surgeon room.
WO2008088645A3 (en) Trans urinary bladder access device and method
WO2005105037A8 (en) Use of a viscoelastic composition for treating increased intraocular pressure
WO2004029769A3 (en) A video game for assisting healing of the human body
JP2007517543A5 (en)
WO2007133520A3 (en) Stent coating comprising titanium oxide or iridium oxide and a therapeutic agent
WO2007041398A3 (en) Treatment of cancer with specific rxr agonists
WO2006009919A3 (en) Improved efficacy of immunotherapy by integrating diagnostic with therapeutic methods
WO2006021040A3 (en) Selective ophthalmic laser treatment
WO2004050140A3 (en) Medical devices for delivery of therapeutic agents
WO2003020202A3 (en) Method for reducing hypertension and heart failure
WO2004028570A3 (en) A method for treating severe tinnitus
WO2008047317A3 (en) System and method for minimally invasive disease therapy
WO2007036881A3 (en) System and method for minimally invasive disease therapy
WO2004110302A3 (en) Methods of delivering anti-restenotic agents from a stent
IL182262A0 (en) Self-fixating scaffolds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase